MX2020012309A - Moleculas de union a gp41 optimizadas y usos de las mismas. - Google Patents

Moleculas de union a gp41 optimizadas y usos de las mismas.

Info

Publication number
MX2020012309A
MX2020012309A MX2020012309A MX2020012309A MX2020012309A MX 2020012309 A MX2020012309 A MX 2020012309A MX 2020012309 A MX2020012309 A MX 2020012309A MX 2020012309 A MX2020012309 A MX 2020012309A MX 2020012309 A MX2020012309 A MX 2020012309A
Authority
MX
Mexico
Prior art keywords
binding molecules
binding
optimized
domain
molecules
Prior art date
Application number
MX2020012309A
Other languages
English (en)
Inventor
Liqin Liu
Barton F Haynes
Guido Ferrari
Jeffrey Lee Nordstrom
Scott Koenig
Leslie S Johnson
Gundo Diedrich
Chia - Ying Kao LAM
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MX2020012309A publication Critical patent/MX2020012309A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a moléculas de unión a gp41 de VIH-1 optimizadas que tienen inmunogenicidad reducida. Más específicamente, la invención se refiere a moléculas de unión a gp41 optimizadas que comprenden un dominio de cadena ligera variable (VL) de unión a gp41 y/o un dominio de cadena pesada variable (VH) de unión a gp41 que se ha o han optimizado para reducir la inmunogenicidad de dichos dominios luego de la administración a un sujeto receptor. La invención se refiere en particular a moléculas de unión a gp41 que son moléculas de unión a gp41 multiespecíficas (incluyendo diacuerpos biespecíficos (incluidos los diacuerpos DART(r)), BiTE(r)s, anticuerpos biespecíficos, moléculas de unión trivalentes (incluyendo moléculas TRIDENT(tm)), etc.) que comprenden: (i) tales dominios variables de unión a gp41 optimizados y (ii) un dominio capaz de unirse a un epítopo de una molécula presente en la superficie de una célula efectora. La invención también está dirigida a composiciones farmacéuticas que comprenden cualquiera de tales moléculas de unión a gp41, y a métodos que implican el uso de cualquiera de dichas moléculas de unión a gp41 en el tratamiento de la infección por VIH-1.
MX2020012309A 2018-05-18 2019-05-13 Moleculas de union a gp41 optimizadas y usos de las mismas. MX2020012309A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862673462P 2018-05-18 2018-05-18
PCT/US2019/032030 WO2019222104A1 (en) 2018-05-18 2019-05-13 Optimized gp41-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2020012309A true MX2020012309A (es) 2021-06-08

Family

ID=68540936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012309A MX2020012309A (es) 2018-05-18 2019-05-13 Moleculas de union a gp41 optimizadas y usos de las mismas.

Country Status (12)

Country Link
US (1) US20210246194A1 (es)
EP (1) EP3794027A4 (es)
JP (1) JP2021524451A (es)
CN (1) CN112533945A (es)
AU (1) AU2019269383A1 (es)
BR (1) BR112020023432A2 (es)
CA (1) CA3100398A1 (es)
IL (1) IL278832A (es)
MX (1) MX2020012309A (es)
SG (1) SG11202011355QA (es)
WO (1) WO2019222104A1 (es)
ZA (1) ZA202007056B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
JP6839075B2 (ja) * 2014-09-26 2021-03-03 マクロジェニクス，インコーポレーテッド Ｃｄ１９及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用
WO2019118266A1 (en) * 2017-12-12 2019-06-20 Macrogenics Inc. Bispecific cd 16-binding molecules and their use in the treatment of disease
CN111647078B (zh) * 2020-06-22 2022-04-26 中国医学科学院医学生物学研究所 一种抗hiv的单克隆抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009036379A2 (en) * 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
HUE055845T2 (hu) * 2013-03-14 2021-12-28 Macrogenics Inc Aktiváló receptort expresszáló immuneffektor sejtekkel immunreaktív bispecifikus molekulák
WO2015013390A1 (en) * 2013-07-25 2015-01-29 Pincus Seth Anti-hiv dual specificity antibodies and methods of hiv treatment
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
WO2016054101A1 (en) * 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2016168758A1 (en) * 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.

Also Published As

Publication number Publication date
CN112533945A (zh) 2021-03-19
SG11202011355QA (en) 2020-12-30
BR112020023432A2 (pt) 2021-02-23
WO2019222104A1 (en) 2019-11-21
ZA202007056B (en) 2021-10-27
CA3100398A1 (en) 2019-11-21
US20210246194A1 (en) 2021-08-12
JP2021524451A (ja) 2021-09-13
EP3794027A1 (en) 2021-03-24
IL278832A (en) 2021-01-31
EP3794027A4 (en) 2022-02-09
AU2019269383A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
MX2020012309A (es) Moleculas de union a gp41 optimizadas y usos de las mismas.
PH12018502204A1 (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
UY37127A (es) Moléculas de unión a ror1, y métodos de uso de las mismas
PH12016502590B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
EP4257600A3 (en) Antibodies that target hiv gp120 and methods of use
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EP4349411A3 (en) Anti-pd-1 antibodies and uses thereof
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
PH12020552229A1 (en) Il-11ra antibodies
NZ595235A (en) Compositions and methods for increasing muscle growth
MY188237A (en) Anti-pd-l1 antibodies and uses thereof
EA201890447A1 (ru) Гуманизированные антитела к рецептору ccr7
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2018009913A (es) Aglutinantes max como moduladores myc y sus usos.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.